Publicaciones en colaboración con investigadores/as de Mayo Clinic (20)

2023

  1. A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk

    International Journal of Cancer, Vol. 152, Núm. 2, pp. 239-248

  2. Identification of novel genetic loci for risk of multiple myeloma by functional annotation

    Leukemia

  3. Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization

    International Journal of Molecular Sciences, Vol. 24, Núm. 10

  4. Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients

    Seminars in Hematology

  5. Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients

    Seminars in Hematology

  6. Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials

    Seminars in Hematology

2022

  1. High frequency of central nervous system involvement in transformed Waldenstrom € macroglobulinemia

    Blood Advances

2021

  1. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group

    The Lancet Oncology, Vol. 22, Núm. 3, pp. e119-e130

2020

  1. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

    Blood, Vol. 136, Núm. 21, pp. 2401-2409

  2. A prognostic index predicting survival in transformed Waldenström macroglobulinemia

    Haematologica, Vol. Online ahead of print

2019

  1. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

    The Lancet Oncology, Vol. 20, Núm. 6, pp. e302-e312

2016

  1. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

  2. Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia

    British Journal of Haematology, Vol. 175, Núm. 1, pp. 77-86

  3. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia

    Blood, Vol. 128, Núm. 10, pp. 1321-1328

2014

  1. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus

    Blood, Vol. 124, Núm. 9, pp. 1404-1411

2013

  1. International myeloma working group recommendations for the treatment of multiple myeloma-related bone disease

    Journal of Clinical Oncology, Vol. 31, Núm. 18, pp. 2347-2357

2010

  1. The use of biochemical markers of bone remodeling in multiple myeloma: A report of the International Myeloma Working Group

    Leukemia, Vol. 24, Núm. 10, pp. 1700-1712

2009

  1. International prognostic scoring system for Waldenström macroglobulinemia

    Blood, Vol. 113, Núm. 18, pp. 4163-4170

2007

  1. 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis

    British Journal of Haematology, Vol. 136, Núm. 1, pp. 80-86

2006

  1. Update on recommendations for assessing response from the Third International Workshop on Waldenström's macroglobulinemia

    Clinical Lymphoma and Myeloma, Vol. 6, Núm. 5, pp. 380-383